Exploring Fenfluramine. To explore a different substance…

Names:
Fenfluramine · N-Ethyl-3-(trifluoromethyl)amphetamine
IUPAC name:
N-Ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
ID: 419 · Formula: C12H16F3N · Molecular weight: 231.257
InChI: InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3

Trachsel, D. Fluorine in psychedelic phenethylamines. Drug Test. Analysis, 1 Jul 2012, 4 (7-8), 577-590. 1.0 MB. http://dx.doi.org/10.1002/dta.413

Cozzi, NV. Pharmacological studies of some psychoactive phenylalkylamines: entactogens, hallucinogens, and anorectics. Ph. D. Thesis, University Of Wisconsin-Madison, 1 Jan 1994. 10.6 MB.

Rothman, RB; Blough, BE; Baumann, MH. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J., 2007, 9 (1), E1–E10. 999 kB. http://dx.doi.org/10.1208/aapsj0901001

Partilla, JS; Dempsey, AG; Nagpal, AS; Blough, BE; Baumann, MH; Rothman, RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther., 1 Oct 2006, 319 (1), 237–246. 367 kB. http://dx.doi.org/10.1124/jpet.106.103622

Rothman, RB; Blough, BE; Baumann, MH. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. Trends Pharmacol. Sci., 1 Dec 2006, 27 (12), 612–618. 519 kB. http://dx.doi.org/10.1016/j.tips.2006.10.006

Marona-Lewicka, D; Nichols, DE. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol. Biochem. Behav., 1 Jan 2007, 87 (4), 453–461. 266 kB. http://dx.doi.org/10.1016/j.pbb.2007.06.001

De Felice, LJ; Glennon, RA; Negus, SS. Synthetic cathinones: Chemical phylogeny, physiology, and neuropharmacology. Life Sci., 27 Feb 2014, 97 (1), 20–26. 697 kB. http://dx.doi.org/10.1016/j.lfs.2013.10.029

Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. http://dx.doi.org/10.1016/j.forsciint.2011.11.003

Cozzi, NV; Frescas, SP; Marona-Lewicka, D; Huang, X; Nichols, DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol. Biochem. Behav., 1 Jan 1998, 59 (3), 709–715. 110 kB. http://dx.doi.org/10.1016/S0091-3057(97)00557-1

Marona-Lewicka, D; Rhee, G; Sprague, JE; Nichols, DE. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav., 1 Jan 1996, 53 (1), 99–105. 1.0 MB. http://dx.doi.org/10.1016/0091-3057(95)00205-7

McKenna, DJ; Guan, AM; Shulgin, AT. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol. Biochem. Behav., 1 Jan 1991, 38 (3), 505–12. 783 kB. http://dx.doi.org/10.1016/0091-3057(91)90005-M

Johnson, MP; Nichols, DE. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol. Biochem. Behav., 1 Jan 1990, 36 (1), 105–109. 521 kB. http://dx.doi.org/10.1016/0091-3057(90)90133-3

Baumgarten, HG; Lachenmayer, L. Serotonin neurotoxins—past and present. Neurotox. Res., 1 Jan 2004, 6 (7–8), 589–614. 402 kB. http://dx.doi.org/10.1007/BF03033455

3-TFMA · Norfenfluramine
N-Et-3-TFMPEA
EA · Etilamfetamine
N-Et-3-FA · 3-Fluoroethamphetamine
N-Et-3-CA
N-Et-3-BA
N-Et-3-IA
N-Et-3-NO2A
N-Et-3-HA
N-Et-3-MA
TFMPP
1477
3-TFMA · Norfenfluramine
N-Et-3-TFMPEA
EA · Etilamfetamine
N-Et-3-FA · 3-Fluoroethamphetamine
N-Et-3-CA
N-Et-3-BA
N-Et-3-IA
N-Et-3-NO2A
N-Et-3-HA
N-Et-3-MA
TFMPP
1477
19 February 2017 · Creative Commons BY-NC-SA ·